Revenue (Quarterly) Chart

View Revenue (Quarterly) for AVNS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
March 31, 2026 182.20M
December 31, 2025 180.90M
September 30, 2025 177.80M
June 30, 2025 175.00M
March 31, 2025 167.50M
December 31, 2024 179.60M
September 30, 2024 170.40M
June 30, 2024 171.70M
March 31, 2024 166.10M
December 31, 2023 173.30M
September 30, 2023 171.30M
June 30, 2023 169.40M
March 31, 2023 159.30M
December 31, 2022 181.60M
September 30, 2022 172.30M
June 30, 2022 170.90M
March 31, 2022 197.40M
December 31, 2021 193.40M
September 30, 2021 184.10M
June 30, 2021 186.40M
March 31, 2021 180.70M
December 31, 2020 185.00M
September 30, 2020 185.70M
June 30, 2020 163.70M
March 31, 2020 180.40M
Date Value
December 31, 2019 189.80M
September 30, 2019 171.40M
June 30, 2019 172.20M
March 31, 2019 164.20M
December 31, 2018 169.90M
September 30, 2018 165.10M
June 30, 2018 160.90M
March 31, 2018 156.40M
December 31, 2017 166.30M
September 30, 2017 150.50M
June 30, 2017 149.10M
March 31, 2017 145.70M
December 31, 2016 410.00M
September 30, 2016 397.50M
June 30, 2016 400.00M
March 31, 2016 384.80M
December 31, 2015 401.40M
September 30, 2015 389.50M
June 30, 2015 389.30M
March 31, 2015 394.20M
December 31, 2014 439.40M
September 30, 2014 408.50M
June 30, 2014 413.50M
March 31, 2014 410.70M
December 31, 2013 431.30M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Boston Scientific Corp. 5.203B
Embecta Corp. 221.80M
Abbott Laboratories 11.16B
AngioDynamics, Inc. 78.42M
Alphatec Holdings, Inc. 192.11M